Pharming says it's closing in on Rhucin approval
Pharming says that the positive interim results it has received from a study of Rhucin is blazing the way to EMEA approval. The Amsterdam-based developer says it expects EMEA approval in the fourth quarter and should be able to launch the drug, which treats hereditary angioedema, in early '08. The company says it is also just weeks away from completing a U.S. study, and should be able to submit data from that trial for FDA approval. Pharming expects the therapy should garner up to €600 million a year in both the U.S. and Europe. The drug developer's shares jumped about 25 percent on the news.
- see Pharming's release
- and here's the report from ABC Money
Related Articles:
Pharming inks creative drug partnering pact. Report
Pharming wins fast track review, shares jump. Report
Pharming gets orphan status for transgenic therapy. Report
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


